Tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can result in prolonged and deep responses in many patients. In such cases, can TKIs be safely discontinued to avoid adverse side effects and costs? Here, Etab Atallah discusses the current issues surrounding TKI discontinuation in CML.
Two editorials provide differing opinions on using pembrolizumab with pemetrexed and platinum chemotherapy for non-small cell lung cancer. In the first article, Stephen Liu argues for embracing this new treatment option, while in the second, Sally Lau and Natasha Leighl argue for a little more caution.
Neoadjuvant chemotherapy can be so effective at shrinking breast tumors in some patients that it has raised the possibility of avoiding surgery altogether. Here, Henry Kuerer discusses exciting recent advances in this area.
Fertility-sparing surgery is an important option for young women with ovarian cancer but there are questions surrounding its safety in all cases. Here, Philippe Morice and Sébastien Gouy discuss the problems faced in high-risk cases.
Tremendous advances have been made in the treatment of ALK-positive lung cancers. Here, Advisory Board member Fiona Blackhall summarizes recent developments in the field and discusses current management hurdles, including development of resistance to ALK inhibitors.